Cooperative therapeutic action of retinoic acid receptor and retinoid x receptor agonists in a mouse model of Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 42, Issue 2, 2014, Pages 587-605

  Kawahara, Kohichi ^a   Suenobu, Michita ^a   Ohtsuka, Hideyuki ^a   Kuniyasu, Akihiko ^a   Sugimoto, Yukihiko ^a   Nakagomi, Madoka ^b   Fukasawa, Hiroshi ^b   Shudo, Koichi ^b   Nakayama, Hitoshi ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b Kawasaki   (Japan)

Author keywords

Alzheimer's disease; Am80; amyloid peptides; HX630; interleukin 4; memory improvement

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; BETA ACTIN; HX 630; INSULINASE; INTERLEUKIN 4; MESSENGER RNA; NOOTROPIC AGENT; RETINOIC ACID RECEPTOR; RETINOID X RECEPTOR; TAMIBAROTENE; UNCLASSIFIED DRUG; BENZAZEPINE DERIVATIVE; BENZOIC ACID DERIVATIVE; NEUROLEPTIC AGENT; TETRALIN DERIVATIVE;

ALZHEIMER DISEASE; AMNESIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BRAIN CORTEX; CEREBELLUM; CONTROLLED STUDY; FEMALE; HEMISPHERE; HIPPOCAMPUS; IN VITRO STUDY; IN VIVO STUDY; MALE; MICROGLIA; MOUSE; NONHUMAN; RAT; UPREGULATION; AGONISTS; ANIMAL; BRAIN; C57BL MOUSE; CELL CULTURE; CHEMISTRY; DISEASE MODEL; DRUG COMBINATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MAZE TEST; METABOLISM; MUTATION; NEWBORN; PATHOLOGY; TIME; TRANSGENIC MOUSE; WISTAR RAT;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANIMALS, NEWBORN; ANTIPSYCHOTIC AGENTS; BENZAZEPINES; BENZOATES; BRAIN; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; GENE EXPRESSION REGULATION; HUMANS; INSULYSIN; MALE; MAZE LEARNING; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROGLIA; MUTATION; RATS; RATS, WISTAR; RECEPTORS, RETINOIC ACID; RETINOID X RECEPTORS; TETRAHYDRONAPHTHALENES; TIME FACTORS;

EID: 84916878837     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-132720     Document Type: Article

References (77)

1. Krstic D, Knuesel I (2013) Deciphering the mechanism underlying late-onset Alzheimer's disease. Nat Rev Neurol 9, 25-34.
2. Vom Berg J, Prokop S, Miller KR, Obst J, Kälin RE, Lopategui-Cabezas I, Wegner A, Mair F, Schipke CG, Peters O, Winter Y, Becher B, Heppner FL (2012) Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease-like pathology and cognitive decline. Nat Med 18, 1812-1819.
3. Heneka MT, Kummer MP, Stutz A, Delekate A, Schwartz S, Vieira-Saecker A, Griep A, Axt D, Remus A, Tzeng TC, Gelpi E, Halle A, Korte M, Latz E, Golenbock DT (2013) NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature 493, 674-678.
4. Sporn MB, Roberts AB, Goodman DS, Gudas LJ (1994) The Retinoids: Biology, Chemistry, and Medicine, 2nd ed, Raven Press, New York.
5. Corcoran JP, So PL, Maden M (2004) Disruption of the retinoid signalling pathway causes a deposition of amyloid in the adult rat brain. Eur J Neurosci 20, 896-902.
6. Prinzen C, Müller U, Endres K, Fahrenholz F, Postina R (2005) Genomic structure and functional characterization of the human ADAM10 promoter. FASEB J 19, 1522-1524.
7. Tippmann F, Hundt J, Schneider A, Endres K, Fahrenholz F (2009) Up-regulation of the secretase ADAM10 by retinoic acid receptors and acitretin. FASEB J 23, 1643-1654.
8. Jarvis CI, Goncalves MB, Clarke E, Dogruel M, Kalindjian SB, Thomas SA, Maden M, Corcoran JP (2010) Retinoic acid receptor- signalling antagonizes both intracellular and extracellular amyloid- production and prevents neuronal cell death caused by amyloid-. Eur J Neurosci 32, 1246-1255.
9. Koryakina A, Aeberhard J, Kiefer S, Hamburger M, Küenzi P (2009) Regulation of secretases by all-trans-retinoic acid. FEBS J 276, 2645-2655.
10. Lichtenthaler SF (2011) Secretase in Alzheimer's disease: Molecular identity, regulation and therapeutic potential. J Neurochem 116, 10-21.
11. Endres K, Fahrenholz F (2012) Regulation of secretase ADAM10 expression and activity. Exp Brain Res 217, 343-352.
12. Goodman AB, Pardee AB (2003) Evidence for defective retinoid transport and function in late onset Alzheimer's disease. Proc Natl Acad Sci U S A 100, 2901-2905.
13. Shudo K, Kagechika H, Yamazaki N, Igarashi M, Takeda C (2004) A synthetic retinoid Am80 (tamibarotene) rescues the memory deficit caused by scopolamine in a passive avoidance paradigm. Biol Pharm Bull 27, 1887-1889.
14. Ding Y, Qiao A, Wang Z, Goodwin JS, Lee ES, Block ML, Allsbrook M, McDonald MP, Fan GH (2008) Retinoic acid attenuates amyloid deposition and rescues memory deficits in an Alzheimer's disease transgenic mouse model. J Neurosci 28, 11622-11634.
15. Kawahara K, Nishi K, Suenobu M, Ohtsuka H, Maeda A, Nagatomo K, Kuniyasu A, Staufenbiel M, Nakagomi M, Shudo K, Nakayama H (2009) Oral administration of synthetic retinoid Am80 (Tamibarotene) decreases brain amyloid peptides in APP23 mice. Biol Pharm Bull 32, 1307-1309.
16. Cramer PE, Cirrito JR, Wesson DW, Lee CY, Karlo JC, Zinn AE, Casali BT, Restivo JL, Goebel WD, James MJ, Brunden KR, Wilson DA, Landreth GE (2012) ApoE-directed therapeutics rapidly clear amyloid and reverse deficits in AD mouse models. Science 335, 1503-1506.
17. Goncalves MB, Clarke E, Hobbs C, Malmqvist T, Deacon R, Jack J, Corcoran JP (2013) Amyloid inhibits retinoic acid synthesis exacerbating Alzheimer disease pathology which can be attenuated by an retinoic acid receptor agonist. Eur J Neurosci 37, 1182-1192.
18. Fitz NF, Cronican AA, Lefterov I, Koldamova R (2013) Comment on "ApoE-directed therapeutics rapidly clear amyloid and reverse deficits inADmouse models". Science 340, 924-c.
19. Price AR, Xu G, Siemienski ZB, Smithson LA, Borchelt DR, Golde TE, Felsenstein KM (2013) Comment on "ApoEdirected therapeutics rapidly clear amyloid and reverse deficits in AD mouse models". Science 340, 924-d.
20. Tesseur I, Lo AC, Roberfroid A, Dietvorst S, Van Broeck B, Borgers M, Gijsen H, Moechars D, Mercken M, Kemp J, D'Hooge R, De Strooper B (2013) Comment on "ApoEdirected therapeutics rapidly clear amyloid and reverse deficits in AD mouse models". Science 340, 924-e.
21. Veeraraghavalu K, Zhang C, Miller S, Hefendehl JK, Rajapaksha TW, Ulrich J, Jucker M, Holtzman DM, Tanzi RE, Vassar R, Sisodia SS (2013) Comment on "ApoE-directed therapeutics rapidly clear amyloid and reverse deficits in AD mouse models". Science 340, 924-f.
22. LaClair KD, Manaye KF, Lee DL, Allard JS, Savonenko AV, Troncoso JC, Wong PC (2013) Treatment with bexarotene, a compound that increases apolipoprotein-E, provides no cognitive benefit in mutant APP/PS1 mice. Mol Neurodegener 8, 18.
23. Ross AC (2012) Vitamin A and retinoic acid in T cell-related immunity. Am J Clin Nutr 96, 1166S-1172S.
24. Iwata M, Eshima Y, Kagechika H (2003) Retinoic acids exert direct effects on T cells to suppress Th1 development and enhance Th2 development via retinoic acid receptors. Int Immunol 15, 1017-1025.
25. Gadani SP, Cronk JC, Norris GT, Kipnis J (2012) IL-4 in the brain: A cytokine to remember. J Immunol 189, 4213-4219.
26. Derecki NC, Cardani AN, Yang CH, Quinnies KM, Crihfield A, Lynch KR, Kipnis J (2010) Regulation of learning and memory by meningeal immunity: A key role for IL-4. J Exp Med 207, 1067-1080.
27. Delescluse C, Cavey MT, Martin B, Bernard BA, Reichert U, Maignan J, Darmon M, Shroot B (1991) Selective high affinity retinoic acid receptor alpha or beta-gamma ligands. Mol Pharmacol 40, 556-562.
28. Amano Y, Noguchi M, Nakagomi M, Muratake H, Fukasawa H, Shudo K (2013) Design, synthesis and evaluation of retinoids with novel bulky hydrophobic partial structures. Bioorg Med Chem 21, 4342-4350.
29. Ishida S, Shigemoto-Mogami Y, Kagechika H, Shudo K, Ozawa S, Sawada J, Ohno Y, Inoue K (2003) Clinically potential subclasses of retinoid synergists revealed by gene expression profiling. Mol Cancer Ther 2, 49-58.
30. Nishimaki-Mogami T, Tamehiro N, Sato Y, Okuhira K, Sai K, Kagechika H, Shudo K, Abe-Dohmae S, Yokoyama S, Ohno Y, Inoue K, Sawada J (2008) The RXR agonists PA024 and HX630 have different abilities to activate LXR/RXR and to induce ABCA1 expression in macrophage cell lines. Biochem Pharmacol 76, 1006-1013.
31. Kagechika H, Kawachi E, HashimotoY, ShudoK(1984) New type inducers of differentiation of human HL-60 promyelocytic leukemia cells. Terephthalic anilides. Chem Pharm Bull 32, 4209-4212.
32. Umemiya H, Fukasawa H, Ebisawa M, Eyrolles L, Kawachi E, Eisenmann G, Gronemeyer H, Hashimoto Y, Shudo K, Kagechika H (1997) Regulation of retinoidal actions by diazepinylbenzoic acids. Retinoid synergists which activate the RXR-RAR heterodimers. J Med Chem 40, 4222-4234.
33. Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, Ledermann B, Bürki K, Frey P, Paganetti PA, Waridel C, Calhoun ME, Jucker M, Probst A, Staufenbiel M, Sommer B (1997) Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci U S A 94, 13287-13292.
34. Shimizu E, Kawahara K, Kajizono M, Sawada M, Nakayama H (2008) IL-4-induced selective clearance of oligomeric amyloid peptide1-42 by rat primary type 2 microglia. J Immunol 181, 6503-6513.
35. Ohsawa K, ImaiY, Nakajima K,Kohsaka S (1997) Generation and characterization of a microglial cell line, MG5, derived from a p53-deficient mouse. Glia 21, 285-298.
36. Dam DV, D'Hooge R, Staufenbiel M, Ginneken CV, Meir FV, De Deyn PP (2003) Age-dependent cognitive decline in the APP23 model precedes amyloid deposition. Eur J Neurosci 17, 388-396.
37. Ishido M, Shudo K (2009) Oral administration of synthetic retinoid Am80 inhibits the development of type 1 diabetes in non-obese diabetic (NOD) mice. Biol Pharm Bull 32, 157-159.
38. Morris R (1984) Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 11, 47-60.
39. Vorhees CV,Williams MT (2006) Morris water maze: Procedures for assessing spatial and related forms of learning and memory. Nat Protoc 1, 848-858.
40. Iwata N, Takaki Y, Fukami S, Tsubuki S, Saido TC (2002) Region-specific reduction of A-degrading endopeptidase, neprilysin, in mouse hippocampus upon aging. J Neurosci Res 70, 493-500.
41. Huang SM, Mouri A, Kokubo H, Nakajima R, Suemoto T, Higuchi M, Staufenbiel M, NodaY,Yamaguchi H, Nabeshima T, Saido TC, Iwata N (2006) Neprilysin-sensitive synapseassociated amyloid- peptide oligomers impair neuronal plasticity and cognitive function. J Biol Chem 281, 17941-17951.
42. Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162, 156-159.
43. Mildner A, Schlevogt B, Kierdorf K, Böttcher C, Erny D, Kummer MP, Quinn M, Brück W, Bechmann I, Heneka MT, Priller J, Prinz M (2011) Distinct and non-redundant roles of microglia and myeloid subsets in mouse models of Alzheimer's disease. J Neurosci 31, 11159-11171.
44. Yamanaka M, Ishikawa T, Griep A, Axt D, Kummer MP, Heneka MT (2012) PPAR/RXR-induced and CD36-mediated microglial amyloid- phagocytosis results in cognitive improvement in amyloid precursor protein/ presenilin 1 mice. J Neurosci 32, 17321-17331.
45. Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM (1998) PPAR promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93, 241-252.
46. Heyman RA, Mangelsdorf DJ, Dyck JA, Stein RB, Eichele G, Evans RM, Thaller C (1992) 9-cis Retinoic acid is a high affinity ligand for the retinoid X receptor. Cell 68, 397-406.
47. Miwako I, Kagechika H (2007) Tamibarotene. Drugs Today 43, 563-568.
48. Solomin L, Johansson CB, Zetterström RH, Bissonnette RP, Heyman RA, Olson L, Lendahl U, Frisén J, PerlmannT(1998) Retinoid-X receptor signalling in the developing spinal cord. Nature 395, 398-402.
49. Zhang C, Hazarika P, Ni X, Weidner DA, Duvic M (2002) Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: Relevance to mechanism of therapeutic action. Clin Cancer Res 8, 1234-1240.
50. Kagechika H, Shudo K (2005) Synthetic retinoids: Recent developments concerning structure and clinical utility. J Med Chem 48, 5875-5883.
51. Oddo S, Caccamo A, Smith IF, Green KN, LaFerlaFM(2006) A dynamic relationship between intracellular and extracellular pools of A. Am J Pathol 168, 184-194.
52. Tomiyama T, Matsuyama S, Iso H, Umeda T, Takuma H, Ohnishi K, Ishibashi K, Teraoka R, Sakama N, Yamashita T, Nishitsuji K, Ito K, Shimada H, Lambert MP, Klein WL, Mori H (2010) A mouse model of amyloid oligomers: Their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo. J Neurosci 30, 4845-4856.
53. Melino G, Draoui M, Bernardini S, Bellincampi L, Reichert U, Cohen P (1996) Regulation by retinoic acid of insulindegrading enzyme and of a related endoprotease in human neuroblastoma cell lines. Cell Growth Differ 7, 787-796.
54. Bulloj A, Leal MC, Surace EI, Zhang X, Xu H, Ledesma MD, Castaño EM,Morelli L (2008) Detergent resistant membraneassociated IDE in brain tissue and cultured cells: Relevance to A and insulin degradation. Mol Neurodegener 3, 22.
55. Killick R, Scales G, Leroy K, Causevic M, Hooper C, Irvine EE, Choudhury AI, Drinkwater L, Kerr F, Al-Qassab H, Stephenson J, Yilmaz Z, Giese KP, Brion JP, Withers DJ, Lovestone S (2009) Deletion of Irs2 reduces amyloid deposition and rescues behavioural deficits in APP transgenic mice. Biochem Biophys Res Commun 386, 257-262.
56. Zhao Z, Xiang Z, Haroutunian V, Buxbaum JD, Stetka B, PasinettiGM(2007) Insulin degrading enzyme activity selectively decreases in the hippocampal formation of cases at high risk to develop Alzheimer's disease. Neurobiol Aging 28, 824-830.
57. Qiu WQ, Walsh DM, Ye Z, Vekrellis K, Zhang J, Podlisny MB, Rosner MR, Safavi A, Hersh LB, Selkoe DJ (1998) Insulin-degrading enzyme regulates extracellular levels of amyloid protein by degradation. J Biol Chem 273, 32730-32738.
58. Maghsoodi B, Poon MM, Nam CI, Aoto J, Ting P, Chen L (2008) Retinoic acid regulates RAR-mediated control of translation in dendritic RNA granules during homeostatic synaptic plasticity. Proc Natl Acad Sci U S A 105, 16015-16020.
59. Poon MM, Chen L (2008) Retinoic acid-gated sequencespecific translational control by RAR. Proc Natl Acad Sci U S A 105, 20303-20308.
60. Higuchi M, Iwata N, MatsubaY, Takano J, Suemoto T, Maeda J, Ji B, Ono M, Staufenbiel M, Suhara T, Saido TC (2012) Mechanistic involvement of the calpain-calpastatin system in Alzheimer neuropathology. FASEB J 26, 1204-1217.
61. Kalinin S, Richardson JC, Feinstein DL (2009) A PPAR? agonist reduces amyloid burden and brain inflammation in a transgenic mouse model of Alzheimer's disease. Curr Alzheimer Res 6, 431-437.
62. Takeda N, Manabe I, Shindo T, Iwata H, Iimuro S, Kagechika H, Shudo K, Nagai R (2006) Synthetic retinoid Am80 reduces scavenger receptor expression and atherosclerosis in mice by inhibiting IL-6. Arterioscler Thromb Vasc Biol 26, 1177-1183.
63. Kawahara K, Suenobu M, Yoshida A, Koga K, Hyodo A, Ohtsuka H, Kuniyasu A, Tamamaki N, Sugimoto Y, Nakayama H (2012) Intracerebral microinjection of interleukin-4/interleukin-13 reduces-amyloid accumulation in the ipsilateral side and improves cognitive deficits in young amyloid precursor protein 23 mice. Neuroscience 207, 243-260.
64. Fenn AM, Henry CJ, Huang Y, Dugan A, Godbout JP (2012) Lipopolysaccharide-induced interleukin (IL)-4 receptor- expression and corresponding sensitivity to theM2promoting effects of IL-4 are impaired in microglia of aged mice. Brain Behav Immun 26, 766-777.
65. Nolan Y, Maher FO, Martin DS, Clarke RM, Brady MT, Bolton AE, Mills KH, Lynch MA (2005) Role of interleukin- 4 in regulation of age-related inflammatory changes in the hippocampus. J Biol Chem 280, 9354-9362.
66. Zhu B, Buttrick T, Bassil R, Zhu C, Olah M, Wu C, Xiao S, OrentW, ElyamanW, Khoury SJ (2013) IL-4 and retinoic acid synergistically induce regulatory dendritic cells expressing Aldh1a2. J Immunol 191, 3139-3151.
67. Carpentier A, Balitrand N, Rochette-Egly C, Shroot B, Degos L, Chomienne C (1997) Distinct sensitivity of neuroblastoma cells for retinoid receptor agonists: Evidence for functional receptor heterodimers. Oncogene 15, 1805-1813.
68. Leroy P, Nakshatri H, Chambon P (1991) Mouse retinoic acid receptor 2 isoform is transcribed from a promoter that contains a retinoic acid response element. Proc Natl Acad Sci U S A 88, 10138-10142.
69. Stellwagen D, Malenka RC (2006) Synaptic scaling mediated by glial TNF-. Nature 440, 1054-1059.
70. Chang EH, Savage MJ, Flood DG, Thomas JM, Levy RB, Mahadomrongkul V, Shirao T, Aoki C, Huerta PT (2006) AMPA receptor downscaling at the onset of Alzheimer's disease pathology in double knockin mice. Proc Natl Acad Sci U S A 103, 3410-3415.
71. Montgomery SL, Mastrangelo MA, Habib D, Narrow WC, Knowlden SA, Wright TW, Bowers WJ (2011) Ablation of TNF-RI/RII expression in Alzheimer's disease mice leads to an unexpected enhancement of pathology: Implications for chronic pan-TNF- suppressive therapeutic strategies in the brain. Am J Pathol 179, 2053-2070.
72. Dheen ST, Jun Y, Yan Z, Tay SS, Ling EA (2005) Retinoic acid inhibits expression of TNF- and iNOS in activated rat microglia. Glia 50, 21-31.
73. Hellmann-Regen J, Kronenberg G, Uhlemann R, Freyer D, Endres M, GertzK(2013) Accelerated degradation of retinoic acid by activated microglia. J Neuroimmunol 256, 1-6.
74. Santello M, Volterra A (2012) TNF in synaptic function: Switching gears. Trends Neurosci 35, 638-647.
75. Hickman SE, Allison EK, El Khoury J (2008) Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. J Neurosci 28, 8354-8360.
76. Mizojiri K, Okabe H, Sugeno K, Esumi Y, Takaichi M, Miyake T, Seki H, Inaba A (1997) Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro- 5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 1st communication: Absorption, distribution, metabolism and excretion after topical application and subcutaneous administration in rats. Arzneimittelforschung 47, 59-69.
77. Liu X, Zhang Z, JiangY,HuY,Wang Z, Liu J, Feng R, Zhang J, Huang G (2014) Novel PEG-grafted nanostructured lipid carrier for systematic delivery of a poorly soluble anti-leukemia agent Tamibarotene: Characterization and evaluation. Drug Deliv, doi:10.3109/10717544.2014.885614